KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
A nomogram involving immune-inflammation index for predicting distant metastasis-free survival of major salivary gland carcinoma following postoperative radiotherapy. PMID 36052414 · Cancer Med · 2023-Feb The study is a retrospective prognostic model development and validation for major salivary gland carcinoma patients receiving postoperative radiotherapy. The publication type 'Randomized Controlled Trial' is a misclassification; the randomization described is for splitting the patient cohort into training and validation sets for nomogram construction, not for comparing treatment arms. The intervention is postoperative radiotherapy, a non-drug local therapy, and there is no drug-containing intervention arm. The study does not report results of a Phase III/IIIb or Phase II/III randomized trial of a drug.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Oncological outcome of contralateral submental artery island flap versus primary closure in tongue squamous cell carcinoma: randomized non-inferiority clinical trial. PMID 35672195 · Int J Oral Maxillofac Surg · 2023-Feb The study is a randomized, non-inferiority trial in oncology (tongue squamous cell carcinoma) with human subjects and reports original results. However, it is excluded because it does not involve a drug-containing intervention (compares surgical techniques: submental flap vs. primary closure), is not a Phase III/IIIb or Phase II/III trial, and lacks a primary time-to-event efficacy endpoint (primary outcome is proportion of local recurrence at 12 months, not a time-to-event analysis like OS, PFS, DFS, or Kaplan-Meier curve).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Colorectal Sessile Serrated Lesion Detection Using Linked Color Imaging: A Multicenter, Parallel Randomized Controlled Trial. PMID 35390509 · Clin Gastroenterol Hepatol · 2023-Feb The study is a randomized trial in oncology with a time-to-event efficacy endpoint (SDR reported as HR), but it compares diagnostic imaging modalities (LCI vs WLI), not a drug-containing intervention. Therefore, it does not meet the 'drug-intervention' criterion required for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Robotic-assisted compared with laparoscopic incisional hernia repair following oncologic surgery: short- and long-term outcomes of a randomized controlled trial. PMID 35355200 · J Robot Surg · 2023-Feb 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Mat Pilates improves lower and upper body strength and flexibility in breast cancer survivors undergoing hormone therapy: a randomized controlled trial (HAPiMat study). PMID 35107399 · Disabil Rehabil · 2023-Feb The study is a randomized controlled trial in breast cancer survivors on hormone therapy, but it evaluates an exercise intervention (Mat Pilates) with physical fitness outcomes (strength, flexibility). It does not report a time-to-event efficacy endpoint for the drug (hormone therapy) or the exercise intervention. Phase is not specified, but it is not identified as Phase III. Therefore, it does not meet the core criteria for a definitive drug-intervention RCT with a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
An exploratory clinical trial for concentrated autologous bone marrow aspirate transplantation in the treatment of osteonecrosis of the femoral head. PMID 35103855 · Eur J Orthop Surg Traumatol · 2023-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Comparison of the effects of sufentanil-dominant anaesthesia/analgesia and epidural anaesthesia/analgesia on postoperative immunological alterations, stress responses and prognosis in open hepatectomy: a randomized trial. PMID 38196520 · J Gastrointest Oncol · 2023-Dec-31 The study is a randomized trial in oncology with a drug intervention and reports original results, but it does not meet the key eligibility criterion of having a primary or key secondary time-to-event efficacy endpoint. The primary endpoint is an immunological ratio (IFN-γ/IL-4), and the cancer outcomes are descriptive follow-ups without formal time-to-event analysis. Therefore, it is not eligible for the Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant sintilimab plus chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: a prospective, single-arm, phase II clinical trial (CY-NICE). PMID 38249875 · J Thorac Dis · 2023-Dec-30 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Phase III study of bilayer sustained-release tramadol tablets in patients with cancer pain: a double-blind parallel-group, non-inferiority study with immediate-release tramadol capsules as an active comparator. PMID 38157081 · Support Care Cancer · 2023-Dec-29 The study is a randomized, double-blind, Phase III trial of a drug (tramadol) for cancer pain, but the primary endpoint is change in pain score (VAS), which is not a time-to-event efficacy endpoint (e.g., OS, PFS). It therefore does not meet the key requirement for a time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A prospective randomized study of multimodal analgesia combined with single injection transversus abdominis plane block versus epidural analgesia against postoperative pain after laparoscopic colon cancer surgery. PMID 38157027 · Int J Colorectal Dis · 2023-Dec-29 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Changes in primary endpoints in cancer trials. PMID 38050011 · Drug Ther Bull · 2023-Dec-27 The record is a meta-analysis/review article summarizing endpoint changes across multiple cancer trials. It is not an original Phase III/IIIb or Phase II/III randomized trial with a drug intervention and a primary/key secondary time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Serum-based biomarkers associated with lung cancer risk and cause-specific mortality in the German randomized Lung Cancer Screening Intervention (LUSI) trial. PMID 38205209 · Transl Lung Cancer Res · 2023-Dec-26 The record describes a randomized lung cancer screening trial evaluating serum biomarkers, not a trial of a drug-containing intervention. The required criteria of a drug intervention and a definitive Phase III/IIIb or Phase II/III randomized trial are not met.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Wound healing after therapy of oral potentially malignant disorders with a 445-nm semiconductor laser: a randomized clinical trial. PMID 38147181 · Clin Oral Investig · 2023-Dec-26 Study is a randomized trial in an oncology precursor context, but it compares a laser device to surgery for wound healing outcomes, not a drug intervention, and does not report a time-to-event efficacy endpoint as defined for Kaplan-Meier digitization.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A Nomogram and Risk Classification System Predicting the Prognosis of Patients with De Novo Metastatic Breast Cancer Undergoing Immediate Breast Reconstruction: A Surveillance, Epidemiology, and End Results Population-Based Study. PMID 38248093 · Curr Oncol · 2023-Dec-23 The record is a population-based prognostic nomogram study for breast cancer-specific survival in de novo metastatic breast cancer patients. It is not an original report of a Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint. The study uses a database (SEER) to build a prediction model, not to report trial results. No explicit trial phase is provided, and while it mentions chemotherapy as a factor, it is not a drug intervention trial. The time-to-event outcome (BCSS) is prognostic, not a trial efficacy endpoint. Therefore, it does not meet the eligibility criteria.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Repurposing pantoprazole in combination with systemic therapy in advanced head and neck squamous cell carcinoma: a phase I/II randomized study. PMID 38129716 · Med Oncol · 2023-Dec-21 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Prognostic analysis of percutaneous vertebroplasty (PVP) combined with 125I implantation on lumbosacral vertebral osteoblastic metastases. PMID 38124135 · World J Surg Oncol · 2023-Dec-20 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Nurse navigation, symptom monitoring and exercise in vulnerable patients with lung cancer: feasibility of the NAVIGATE intervention. PMID 38123657 · Sci Rep · 2023-Dec-20 This is a single-arm, non-randomized feasibility study for a planned Phase III trial. It does not have a randomized comparison, is not a definitive Phase III trial, has no drug intervention (only nurse navigation, PROs, and exercise), and does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier or HR.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Development and Validation of a Nomogram for Predicting Postoperative Early Relapse and Survival in Hepatocellular Carcinoma. PMID 38118280 · J Natl Compr Canc Netw · 2023-Dec-20 The record describes a retrospective multicenter study developing a prognostic nomogram for hepatocellular carcinoma. While it is oncology, human, and reports time-to-event endpoints (DFS, OS), it is not a clinical trial evaluating a drug intervention. The study is not randomized in the sense of comparing interventions, and there is no evidence of a Phase III or Phase II/III trial. The 'Randomized Controlled Trial' publication type likely refers to the random splitting of data into training/validation cohorts, not a therapeutic trial. Therefore, it does not meet the core criteria for a drug-intervention randomized trial with a primary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial. PMID 38100992 · J Clin Oncol · 2023-Dec-20 The record describes a randomized, drug-controlled trial with primary efficacy endpoints including survival (a time-to-event measure). The publication type ('Clinical Trial') and the description as a 'definitive trial' provide sufficient evidence for Phase III/definitive status. All required criteria are explicitly met in the abstract.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO). PMID 37733977 · J Clin Oncol · 2023-Dec-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Excellent efficacy and beneficial safety during observational 5-year follow-up of rapid steroid withdrawal after renal transplantation (Harmony FU study). PMID 37391381 · Nephrol Dial Transplant · 2023-Dec-20 This is a non-oncology study focusing on renal transplantation and immunosuppression. It is a post-trial observational follow-up, not an original primary or secondary result report from a Phase III/IIIb or Phase II/III randomized trial. The primary trial was in nephrology, not oncology.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial. PMID 38114518 · Nat Commun · 2023-Dec-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Induction of double-strand breaks with the non-steroidal androgen receptor ligand flutamide in patients on androgen suppression: a study protocol for a randomized, double-blind prospective trial. PMID 38104131 · Trials · 2023-Dec-16 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Evaluating the cost-effectiveness of [18F]FDG-PET/CT for investigation of persistent or recurrent neutropenic fever in high-risk haematology patients. PMID 38102639 · Cancer Imaging · 2023-Dec-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Feasibility of adjuvant self-administered intravaginal 5-fluorouracil cream following primary treatment of cervical intraepithelial neoplasia grade 2 or 3 among women living with HIV in Kenya: study protocol for a pilot trial. PMID 38168442 · medRxiv · 2023-Dec-14 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer. PMID 38097783 · Sci Rep · 2023-Dec-14 The record is a retrospective bioinformatics/prognostic study analyzing public datasets (TCGA, GTEx, GEO) to construct a risk signature. It is not a report of a randomized clinical trial with a drug intervention and a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Analysis of long non-coding RNAs associated with disulfidptosis for prognostic signature and immunotherapy response in uterine corpus endometrial carcinoma. PMID 38097686 · Sci Rep · 2023-Dec-14 The record is an oncology bioinformatics study developing a prognostic signature for uterine corpus endometrial carcinoma. While it involves human data, randomization (for model training/testing), and cancer, it does not represent a Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint. The study analyzes existing data to create a prognostic model; it is not an original clinical trial report of drug efficacy.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
KRAS status predicted by pretreatment MRI radiomics was associated with lung metastasis in locally advanced rectal cancer patients. PMID 38087207 · BMC Med Imaging · 2023-Dec-12 This is a retrospective, multicenter diagnostic/prognostic study developing a radiomic model to predict KRAS status and lung metastasis risk. It meets criteria for oncology, human, randomized (cohort split), and time-to-event analysis, but it lacks a Phase III/IIIb or Phase II/III randomized trial of a drug-containing intervention. The intervention is a predictive model, not a drug therapy.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Three-Week Versus 4-Week Schedule of nab-Paclitaxel in Patients With Metastatic Breast Cancer: A Randomized Phase II Study. PMID 37882706 · Oncologist · 2023-Dec-11 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A Randomized Placebo-Controlled Trial of the Anti-Nerve Growth Factor Antibody Tanezumab in Subjects With Cancer Pain Due to Bone Metastasis. PMID 37343145 · Oncologist · 2023-Dec-11 The study is a randomized, placebo-controlled, Phase III trial in cancer patients with a drug intervention and reports original results. However, the primary efficacy endpoint is change in pain score (a continuous outcome), not a time-to-event endpoint such as OS, PFS, DFS, etc., nor does it report Kaplan-Meier curves or hazard ratios. Therefore, it does not meet the inclusion criteria for a time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Multimodality local consolidative treatment versus conventional care of advanced lung cancer after first-line systemic anti-cancer treatment: study protocol for the RAMON multicentre randomised controlled trial with an internal pilot. PMID 38072470 · BMJ Open · 2023-Dec-10 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649. PMID 37713657 · J Clin Oncol · 2023-Dec-10 命中用户提供的消化道肿瘤阳性参考集。
B
影子组漏检补回 eligiblepositive_reference confirmed 1 Figure · 4 Panel · risk visible
Ivabradine for the Prevention of Anthracycline-Induced Cardiotoxicity in Female Patients with Primarily Breast Cancer: A Prospective, Randomized, Open-Label Clinical Trial. PMID 38138243 · Medicina (Kaunas) · 2023-Dec-09 The study is a randomized, drug-intervention trial in oncology patients, but it is not a Phase III/IIIb or Phase II/III randomized trial with a primary time-to-event efficacy endpoint. The primary endpoint (GLS reduction) is a cardiotoxicity surrogate marker, not a cancer survival or progression endpoint. No Phase is explicitly reported, but the design (48 patients, single-centre) is more consistent with Phase II or pilot. There is no mention of OS, PFS, DFS, or other time-to-event endpoints, nor Kaplan-Meier curves or Hazard Ratios for such outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
ProFertil study protocol for the investigation of gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy aiming at fertility protection of young women and teenagers with cancer in Sweden-a phase III randomised double-blinded placebo-controlled study. PMID 38070906 · BMJ Open · 2023-Dec-09 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
The Intraoperative Administration of Dexmedetomidine Alleviates Postoperative Inflammatory Response in Patients Undergoing Laparoscopy-Assisted Gastrectomy: A Double-Blind Randomized Controlled Trial. PMID 38137474 · Biomedicines · 2023-Dec-08 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: the IPRICE study. PMID 38066522 · BMC Cancer · 2023-Dec-08 The study is a non-randomized, single-center, prospective, interventional trial with a drug-containing intervention (anti-PD-1) for an oncologic human malignancy. However, it is not a randomized controlled trial, is not reported as Phase III/IIIb or a definitive Phase II/III trial, and its primary objective is biomarker identification (predictive factors), not a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS). The abstract does not report results; it is a protocol description. Therefore, it does not meet the eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Incidence of intraoperative hypotension in older patients undergoing total intravenous anesthesia by remimazolam versus propofol: A randomized controlled trial. PMID 38065872 · Medicine (Baltimore) · 2023-Dec-08 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Effect of the Home to Hospital to Home nutrition management program on postoperative liver cancer patients: A single-center randomized controlled study. PMID 38065853 · Medicine (Baltimore) · 2023-Dec-08 The study is a randomized controlled trial in oncology, but it evaluates a non-drug nutrition management program and does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The phase is not specified, and the primary endpoints are nutritional indicators and clinical recovery metrics, not survival or progression.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term outcomes of single-incision plus one-port laparoscopic surgery versus conventional laparoscopic surgery for rectosigmoid cancer: a randomized controlled trial. PMID 38062421 · BMC Cancer · 2023-Dec-07 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG. PMID 37647654 · Blood · 2023-Dec-07 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
'It was a joint plan we worked out together'. How the I-WOTCH programme enabled people with chronic non-malignant pain to taper their opioids: a process evaluation. PMID 38056940 · BMJ Open · 2023-Dec-06 The record describes a process evaluation of a randomized trial for chronic non-malignant pain, not an oncology malignancy trial. It does not report a time-to-event efficacy endpoint (OS, PFS, etc.) from a Phase II/III randomized drug trial. It is a secondary analysis of a non-oncology trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial. PMID 38056900 · J Immunother Cancer · 2023-Dec-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Individualized risk assessment of distant metastases in oral cavity carcinoma: a validated predictive-score model. PMID 37498564 · J Natl Cancer Inst · 2023-Dec-06 The record is a randomized, human, oncology study with a time-to-event endpoint (DM rates, OS). However, it does not involve a drug-containing intervention (patients received surgery with or without radiation/chemoradiation; these are standard-of-care locoregional treatments, not an investigational drug intervention). Furthermore, the primary purpose is prognostic model development and validation, not a report of a randomized trial comparing a drug-containing regimen. Therefore, it is excluded for lack of a drug intervention and for being a secondary/prognostic analysis rather than a primary trial result.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402. PMID 37405857 · J Natl Cancer Inst · 2023-Dec-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group. PMID 38052803 · Blood Cancer J · 2023-Dec-05 The record meets all core eligibility criteria: it is an original report of a randomized trial in a human oncology setting (pediatric APL) with a drug-containing intervention (ATO vs. RIF) and a primary time-to-event efficacy endpoint (5-year EFS). While the explicit phase is not stated in the provided metadata, the trial design (multicenter, randomized, non-inferiority, with a definitive efficacy endpoint) is consistent with a Phase III or equivalent definitive trial. Therefore, it is eligible.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 4 Panel · risk visible
Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance). PMID 38106038 · medRxiv · 2023-Dec-04 The record is a secondary biomarker analysis from a Phase III trial, but it does not report the required time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors. PMID 38067406 · Cancers (Basel) · 2023-Dec-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Gene expression alterations predict the pathological complete response in triple-negative breast cancer exploratory analysis of the NACATRINE trial. PMID 38049525 · Sci Rep · 2023-Dec-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Using biomarkers to allocate patients in a response-adaptive clinical trial. PMID 38045870 · Commun Stat Simul Comput · 2023-Dec-02 The record is a methodological paper discussing a response-adaptive randomization method, using a prior cancer trial as an example. It is not an original result report of a Phase III/IIIb or Phase II/III randomized trial. The abstract does not report time-to-event efficacy results from the referenced trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A multicenter noninferior randomized controlled study of sentinel lymph node biopsy alone versus sentinel lymph node biopsy plus lymphadenectomy for patients with stage I endometrial cancer, INSEC trial concept. PMID 38041023 · BMC Cancer · 2023-Dec-02 The record describes a protocol for a randomized trial comparing surgical techniques (sentinel lymph node biopsy vs. lymphadenectomy) for endometrial cancer. It does not involve a drug intervention and does not present primary trial results, only the trial concept and expected outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -